Next Article in Journal
Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios
Next Article in Special Issue
Does Elderly-Onset Inflammatory Bowel Disease Increase Risk of Colorectal Cancer? A Systematic Review and Meta-Analysis
Previous Article in Journal
Hemodynamic and Hydrodynamic Pathophysiology in Chiari Type 1 Malformations: Towards Understanding the Genesis of Syrinx
Previous Article in Special Issue
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 18
10.3390/jcm12185956
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease

by
Małgorzata Godala
1,*,
Ewelina Gaszyńska
1,
Konrad Walczak
2 and
Ewa Małecka-Wojciesko
3
1
Department of Nutrition and Epidemiology, Medical University of Lodz, 90-752 Lodz, Poland
2
Department of Internal Medicine and Nephrodiabetology, Medical University of Lodz, 90-549 Lodz, Poland
3
Department of Digestive Tract Diseases, Medical University of Lodz, 90-419 Lodz, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(18), 5956; https://doi.org/10.3390/jcm12185956
Submission received: 29 August 2023 / Revised: 10 September 2023 / Accepted: 12 September 2023 / Published: 13 September 2023
(This article belongs to the Special Issue Clinical Advances in Inflammatory Bowel Disease)
Versions Notes

Abstract

:
Inflammatory bowel diseases (IBD) are characterised by multifactorial and chronic inflammation. Much attention has been paid to immune dysfunction in inflammatory bowel diseases. The aim of this study was to assess the usefulness of serum IL-6, IL-1β and IL-10 in determining the activity and nutritional status in IBD patients. The case–control study was carried out on 82 patients with IBD; the control group consisted of 25 clinically healthy subjects. The serum concentrations of IL-6, IL-1 β and IL-10 were determined by the quantitative sandwich enzyme-linked immunosorbent assay. There were no significant differences in IL-6 and IL-1β levels in UC and CD patients according to disease activity as assessed by the Montreal classification, Partial Mayo Score and CDAI. Significantly higher IL-6 levels were found in patients with low body fat in comparison to patients with normal body fat. Furthermore, significantly higher mean IL-6 levels were observed in patients with excess body fat in comparison to patients with normal body fat, and also in comparison to patients with deficient body fat. IL-6 and IL-1β may provide extra information regarding the nutritional status of IBD patients. IL-10 can be considered a non-invasive biomarker of IBD activity.

1. Introduction

Inflammatory bowel diseases (IBDs) are characterised by a multifactorial, as yet not fully understood aetiology and a chronic course with periods of remission and exacerbation. Data gathered over the last few decades reveal that prevalence of inflammatory bowel disease is increasing [1,2,3]. Recent data have shown that IBD affects nearly 100,000 people in Poland, with 23,574 patients with Crohn’s disease (CD) and 73,235 with ulcerative colitis (UC), across all age groups, but the diagnosis is most often made in the third decade of life [1]. The chronic nature of IBD, which is associated with long-term pharmacotherapy, multiple hospitalisations as well as surgical treatment, is a cause of work incapacity and disability [1,2,3,4,5,6,7].
The aetiopathogenesis of IBD is multifactorial. The development of IBD is thought to be influenced by complex interactions between environmental and bacterial factors, genetic predisposition and the disruption of intestinal immune mechanisms [7,8,9,10,11,12,13,14,15,16,17]. Much attention has been paid to immune dysfunction in IBD [3,11]. It has been observed that CD is dominated by the activation of Th1 cell subpopulations [15], which release large amounts of TNF, IFN, IL-2, -6 and -8. In contrast, UC has been shown to activate both Th1 and Th2 cells [17], which is associated with the increased production of immunomodulatory cytokines IL-4, -5, -10 and TNF-α, which support the humoral response by inducing immunoglobulin synthesis. Importantly, there is a group of cytokines, such as IL-1β and IL-6, that play a role in the pathogenesis of both forms of IBD. These substances activate the secondary response of Th1 and Th2 lymphocytes, as a result of the stimulation of immune cells such as macrophages [18].
Interleukin 1 (IL-1) comprises a family of cytokines that includes more than 10 molecules, e.g., IL-1β. IL-1 is one of the main regulators of the inflammatory response, secreted mainly by monocytes and macrophages of various tissues in response to bacterial wall lipopolysaccharide [19,20]. IL-1β is mainly present in its secretory form, almost always released by peripheral blood monocytes and cells isolated from the inflamed gastrointestinal mucosa of IBD patients. IL-1β initiates and exacerbates the inflammatory process in the colon [17,21].
IL-6 is a pro-inflammatory cytokine with pleiotropic effects [22,23]. IL-6 is one of the main factors regulating the body’s defence mechanisms. Together with IL-1β, it initiates and intensifies the inflammatory process in the colon due to its properties stimulating the secretion of other inflammatory mediators (e.g., IL-8 and eicosanoids) [23,24]. The continued stimulation and maintenance of this process damages tissues through the action of released proteolytic enzymes and oxygen free radicals [24,25].
IL-10 is an anti-inflammatory cytokine secreted by Th2 lymphocytes [26,27,28,29]. Studies have shown that mice deficient in IL-10 secretion developed chronic colitis and mucosal proliferation [29]. It was further observed that IL-10 can reduce inflammation in animals and in vitro models, suggesting that it plays a role in reducing Th1-mediated mucosal inflammation [26,29]. Impaired IL-10 production was also noted in both UC and CD [27,28,30].
Generalised inflammation in IBD patients, being a result of excessive cytokine production, leads to a series of metabolic reactions that result in, among others, loss of appetite, increased energy consumption, as well as protein and fat breakdown. This results in the loss of muscle and fat mass, which causes malnutrition in patients with IBD [22,25,31]. Malnutrition is a common problem in IBD patients. It makes therapy less successful and worsens prognosis [1,2,32].
Endoscopy combined with biopsy is the most effective way to diagnose IBD. This method is effective but also invasive and causes discomfort to patients. Therefore, alternative non-invasive biomarkers to assess disease activity are being sought. The aim of this study was to assess the usefulness of serum IL-6, IL-1β and IL-10 in determining the activity and nutritional status in IBD patients.

2. Material and Methods

2.1. Study and Control Groups

In total, 82 patients with IBD (48 patients with CD and 34 patients with UC), recruited from the Medical University of Lodz, participated in the study. The diagnosis of IBD was made on the basis of clinical image, endoscopic, histopathological and imaging studies. Obese patients do not have comorbidities such as diabetes or metabolic syndrome. The control group consisted of 25 healthy volunteers. All studied participants were asked about smoking habit and family history of IBD.
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Bioethics Committee of the Medical University of Lodz (No. RNN/70/22/KE, 14 June 2022). All the subjects gave their written consent to participate in the study.

2.2. Disease Activity

IBD activity was assessed using validated scales. For patients with CD, the Crohn’s Disease Activity Index (CDAI) and the Montreal classification were used [33]. For patients with UC, the Partial Mayo Score and the Montreal classification were used [34].

2.3. Nutritional Status

All subjects had their waist circumference measured and BMI determined. The body composition of the subjects was assessed by Bioelectrical Impedance Analysis (BIA).

2.4. Serum Markers of the Nutritional Status

The serum concentrations of IL-6, IL-1 β and IL-10 were determined by the quantitative sandwich enzyme-linked immunosorbent assay.

2.5. Statistical Analysis

Statistical analysis was performed with the use of Statistica™ 14 software (TIBCO Software Inc., Palo Alto, CA, USA). The normality of distribution was checked using the Shapiro–Wilk W test. In univariate analyses, the Mann–Whitney U test was used for the dichotomous grouping of variables, or the Kruskal–Wallis H test when a grouping variable had more than two categories. Correlations were assessed with the Spearman’s coefficient (r). A level of p < 0.05 was considered statistically significant.

3. Results

3.1. Study Characteristics

The characteristics of the study group are shown in Table 1. In total, 42 women (51.2%) and 40 men (48.8%) with IBD participated in the study. Among the patients, 40 subjects (48.8%) had tertiary education and 14 patients (17.1%) smoked cigarettes. Of all patients, 66 subjects (80.5%) received biological treatment (infliximab, vedolizumab), 64 (78.0%) received 5-aminosalicylic acid preparations, 33 patients (40.2%) received immunosuppressants (azathioprine) and 25 subjects (30.5%) were administered corticosteroids (prednisone). Nearly half of the patients (48.8%) were in the period of clinical remission and did not demonstrate disease symptoms.
No differences were found between patients with IBD and the control group in terms of age, gender and smoking. Furthermore, BMI or waist circumference values were not different in the above groups. However, significant differences were found in the body compositions of the subjects. Patients with IBD demonstrated significantly lower mean contents of body fat.

3.2. Inflammatory Markers in CD and UC

The authors did not find any significant differences in mean Il-6 or IL-1β levels between IBD patients and controls. Significant differences were noted for Il-10, the concentration of which was significantly higher in the UC group than in the control group (19.83 pg/mL vs. 5.30 pg/mL, p = 0.0096), but did not differ significantly between patients with UC and CD or between patients with CD and the control group (Table 2).
There were no differences in the median levels of the cytokines studied by age of the subjects, place of residence, and smoking. In addition, the median IL-1β concentration was significantly higher in the group of men with IBD than in the group of women with IBD (3.0 pg/mL vs. 2.8 pg/mL, p = 0.0422) and in the group of patients with a positive family history (3.1 pg/mL vs. 2.9 pg/mL, p = 0.0437). IL-6 levels were significantly higher in patients with IBD with a positive family history in comparison to those without a family history of inflammatory bowel disease (6.3 pg/mL vs. 5.2 pg/mL, p = 0.0197).

3.3. Inflammatory Markers and Disease Activity

There were no significant differences in IL-1 β and IL-10 levels in IBD patients according to the administration of biological treatment and past intestinal resections. However, patients suffering with the disease for more than 10 years demonstrated significantly higher levels of IL-1β and IL-10 in comparison to other patients (9.6 pg/mL vs. 2.9 pg/mL, p = 0.030 and 14.7 pg/mL vs. 2.5 pg/mL, p = 0.031, respectively). The mean IL-6 levels were found to be significantly lower in patients undergoing biological treatment in comparison to other patients (5.1 pg/mL vs. 6.6 pg/mL, p = 0.0067, respectively) (Table 3).
There were no significant differences in IL-6 and IL-1β levels in UC patients according to disease activity as assessed by the Montreal classification and Partial Mayo Score. Significantly higher IL-10 levels were found in patients in remission in comparison to patients with moderate and severe exacerbations of symptoms (the Partial Mayo Score 0 vs. 2 and 3; 23.6 pg/mL vs. 3.4 pg/mL vs. 2.2 pg/mL, respectively, p = 0.0059). Besides this, higher IL-10 levels were noted in patients with asymptomatic and mild disease flares in comparison to patients with moderate and severe disease flares according to the Montreal classification (24.0 pg/mL vs. 14.7 pg/mL vs. 2.4 pg/mL vs. 2.0 pg/mL, respectively, p = 0.0022) (Table 4). There were no significant differences in IL-6 and IL-1β levels in patients with CD according to disease activity, assessed with the Montreal classification and CDAI. Higher IL-10 levels were found in patients in remission (CDAI < 150) in comparison to patients with mild, moderate and severe symptoms (8.5 pg/mL vs. 1.8 pg/mL vs. 2.3 pg/mL vs. 2.3 pg/mL, respectively, p = 0.0462). No differences were observed in the mean Il-10 levels according to the degree of extension of Crohn’s disease lesions (Table 5).

3.4. Inflammatory Markers and Nutritional Status of Patients

There were no differences in mean serum levels of IL-6, IL-1β and IL-10 according to BMI and waist circumference.
Significantly higher levels of IL-6 and IL-1β were observed in patients who admitted a significant weight loss in the last six months in comparison to patients with a weight loss of less than 10% of the baseline body weight (5.9 pg/mL vs. 4.9 pg/mL, p = 0.048 and 3.0 pg/mL vs. 2.9 pg/mL, p = 0.049, respectively). Furthermore, IL-1β levels positively correlated with muscle mass (rho = 0.2427, p = 0.0280) and lean body mass (rho = 0.2668, p = 0.0154) in patients with IBD.
Significantly higher IL-6 levels were found in patients with low body fat in comparison to patients with normal body fat (5.7 pg/mL vs. 4.6 pg/mL, p = 0.0102). Furthermore, significantly higher mean IL-6 levels were observed in patients with excess body fat in comparison to patients with normal body fat (6.2 pg/mL vs. 4.6 pg/mL, p = 0.0415), and also in comparison to patients with deficient body fat (6.2 vs. 5.7, respectively, p = 0.0078) (Table 6).

3.5. Correlations between Inflammatory Markers

In all participants, IL-10 levels positively correlated with IL-6 (r = 0.2616, p < 0.001) and IL-1β (r = 0.3308, p < 0.0001). Additionally, in all participants, IL-6 levels positively correlated with IL-1β levels (r = 0.3238, p < 0.0001). In CD patients, IL-10 levels positively correlated with IL-6 (r = 0.4129, p < 0.0001) and IL-1β (r = 0.3914, p < 0.001) levels. Furthermore, in the CD group, IL-6 levels positively correlated with IL-1β levels (r = 0.3155, p < 0.001). In the UC group, no significant correlations were found between the studied cytokines (Table 7).

4. Discussion

In our study, we are seeking easily determined biomarkers that may be helpful in assessing nutritional status and IBD activity. Due to the chronic inflammation that occurs in IBD patients, we assessed the usefulness of determining IL-6, IL-1 β and IL-10 levels.
In our study, IL-6 levels did not differ significantly between patients with CD, UC and controls. There was also no correlation between IL-6 levels and disease activity in either the CD or UC groups. The results of other available studies are inconclusive.
A study by Polinska et al. found that the overexpression of IL-6 was noted only in the inflamed mucosa and correlated with disease activity in patients with UC. The authors confirmed its significantly lower levels in UC patients in remission in comparison to patients with active IBD [35].
In a study by Sobolewska et al., IL-6 levels did not differ significantly between patients with CD and UC, and this observation was similar to that in our study. In contrast, they found higher IL-6 levels during clinical exacerbations [36].
Similar data were obtained in a study conducted by Wędrychowicz, in which IL-6 levels increased in the serum of patients with active UC and decreased during remission. Furthermore, IL-6 levels correlated with the severity and extension of inflammatory bowel lesions. IL-6 was also shown to be present in the stool in both the active and inactive phases of UC [37].
In contrast, in a study by Matusiewicz et al., IL-6 levels positively correlated with disease activity in both UC and CD patients [38].
IL-6 strongly stimulates inflammatory processes in a direct manner. In contrast, other pro-inflammatory cytokines, particularly interleukin 1, are factors that stimulate IL-6 production [39]. These data are confirmed by results of our study, in which IL-6 levels positively correlated with IL-1β levels.
On the other hand, we did not confirm significant differences in IL-6 levels between IBD patients and healthy subjects. This was probably affected by the use of biological therapy, which the majority of IBD patients received [39,40]. The administration of biological drugs, especially infliximab, affects the levels inflammatory parameters, including the concentration of pro-inflammatory cytokines [18,41,42,43,44]. Infliximab inhibits TNF-α activity in in vitro bioassays (44lubecka-macura). In vivo, it rapidly forms stable complexes with human TNF-α, which results in a loss of biological activity caused by TNF-α [39,40]. Thus, this treatment reduces the influx of inflammatory cells into the affected areas of the gut and reduces the amount of inflammatory markers. Not only does TNF-α directly affect immune cell function but it also increases the synthesis of cytokines, including IL-6. As a result, IL-6 levels get reduced [39,41]. The effect of diminishing IL-6 levels after biological treatment was confirmed in our study. In fact, we demonstrated significantly lower IL-6 levels in patients receiving biological therapy in comparison to other patients. An implementation of biological treatment and, as a consequence, a decrease in IL-6 levels in these patients possibly explains why there are no differences in mean IL-6 levels between patients and healthy controls.
The present study also assessed IL-1β levels in patients with IBD. Similarly to IL-6, IL-1β levels did not appear to be associated with disease activity in patients with UC and CD, and did not differ significantly from those observed in healthy subjects.
Different data were obtained in a study by Wędrychowicz et al., in which elevated IL-1β levels were found in the stool and serum of patients with UC, especially in the active phase of the disease [37,45]. However, in this study it was noted that the levels of IL-1β secreted into the intestinal lumen did not correlate with systemic inflammatory markers (leukocytosis and increased platelet count) due to its short half-life and accelerated degradation by proteolytic enzymes [45]. This may explain the lack of change in IL-1β levels between healthy subjects and sick patients in the period of symptom exacerbation and remission in our study.
In our study, in addition to pro-inflammatory cytokines, IL-10 levels were also assessed in patients with IBD. IL-10 appeared to have an inhibitory effect on the synthesis of pro-inflammatory cytokines released from T lymphocytes and macrophages in active inflammatory bowel disease, and the administration of IL-10 to patients with UC reduces their complaints [46,47,48,49]. In our study, we found significantly higher IL-10 levels in patients with UC in comparison to healthy controls. However, we did not observe significant differences between patients with UC and CD, or between patients with CD and controls. Importantly, IL-10 levels were associated with disease activity only in UC. Higher levels of this cytokine were noted in patients in remission and with mild flares in comparison to those with moderate and severe disease. Similar data were obtained by other authors.
A study by Wozniak-Stolarska showed elevated serum IL-10 levels in patients with IBD in comparison to healthy subjects [50], and Melgar et al. observed increased IL-10 mRNA levels in the intestinal mucosa of patients with UC in comparison to healthy subjects. This study showed that IL-10 levels correlated with disease activity, and higher levels were observed in patients in remission [51].
The results of a meta-analysis of eight studies evaluating IL-10 levels in patients with IBD, conducted in 2019, appear to be consistent with the results obtained in our study. The meta-analysis showed higher IL-10 levels in patients with UC in comparison to healthy subjects, while these levels did not differ between patients with UC and CD. Furthermore, it was confirmed that increased IL-10 levels contribute to the pathogenesis and progression of UC [52].
The increase in IL-10 levels in IBD patients, especially during remission, is probably due to the body’s response to the increased inflammation that occurs in CD and UC, and an attempt to reduce it. It seems that the inclusion of new, more sensitive markers in the diagnosis and follow-up of patients, in addition to non-specific, standard markers of inflammatory process, would enable one to better assess the patient’s condition and prognosis, and help in choosing optimal therapy. IL-10 deserves special attention in this group.
We further investigated the relationship between the levels of the studied cytokines and the nutritional status of patients with IBD. We found significantly higher mean IL-6 levels among IBD patients with excess body fat. However, we did not observe significant differences in IL-6 levels according to BMI values.
No papers were found that assessed the relationship between IL-6 and the nutritional status of IBD patients. In contrast, the relationship of increased inflammatory processes with obesity has long been discussed in the literature [53,54,55]. A lot of studies have shown that obese individuals demonstrate an increased production of adipokines that promote the development of metabolic diseases related to obesity. These include IL-6 [53,55,56]. The secretory activity of adipose tissue changes and depends on its cellular composition. In addition to adipocytes, adipose tissue contains preadipocytes, lymphocytes, macrophages, mast cells, eosinophils and fibroblasts [55,56]. In obesity, there is a significant influx of macrophages into adipose tissue, which is associated with the development of inflammation. Macrophages in adipose tissue are characterised by a different phenotype and different actions. In the adipose tissue of slim individuals, alternatively activated type II macrophages (macrophages type II, M2) are found, whereas in obese individuals, classically activated type I macrophages (macrophages type I, M1) predominate [54]. Type M1 macrophages are responsible for the development of inflammation. They are activated by cytokines produced by Th1 lymphocytes, which release interferon gamma (IFN-γ). Stimulated M1 macrophages produce pro-inflammatory cytokines, including IL-6 [56]. The results of our study support these observations.
In contrast, in our study, we showed increased IL-6 levels also in subjects with body fat deficiency and reporting a significant weight loss in the last six months. Subjects with body fat deficiency had higher mean IL-6 levels in comparison to patients with normal body fat, but lower levels than patients with excess body fat.
Studies have shown a relationship between IL-6 and eating disorders manifesting with emaciation and body composition abnormalities, including extremely low levels of body fat. In a study conducted by Ziora et al., IL-6 levels were assessed in a group of girls with anorexia nervosa. Mean serum IL-6 levels in patients did not differ significantly from mean levels of this cytokine in a group of healthy girls. In contrast, IL-6 levels were significantly lower in patients with fat deficiency than in the group of obese girls [57]. This relationship was not confirmed by our own study, in which IL-6 levels were significantly higher in the body fat-deficient group than in subjects with normal levels of body fat. It is possible that in underweight patients, high IL-6 levels were related to a great loss of body weight and changes in the body composition. Inflammatory parameters that are observed in IBD are altered in the event of significant reductions in body weight, resulting in reductions in body fat levels [58,59].
In our study, we showed that IL-1β concentration positively correlates with muscle mass content in patients with IBD. However, we did not demonstrate a correlation between IL-1β concentration and the body fat content or BMI of the subjects. The results of studies carried out by other authors on IL-1β values in relation to muscle mass content are inconclusive.
In a study conducted by Ziora et al., patients with mental anorexia and low muscle mass exhibited higher levels of IL-1β than subjects with normal nutritional status [57].
Different data were obtained in a study by Allende et al., in which no significant differences in IL- 1β levels were found in subjects with mental anorexia and in healthy subjects with normal body composition, including normal muscle mass [60].
Our results suggest an association between IL-1β levels and the nutritional status of IBD patients in relation to muscle mass. Changes in body composition, i.e., a decrease in skeletal muscle and adipose tissue mass, resulting in progressive weight loss, are frequently observed in patients with IBD [61,62,63,64,65]. IL-1β is implicated as a cytokine in the development of anorexia associated with chronic disease (most commonly cancer), probably mediated through elevated levels of corticotropin-releasing hormone, which inhibits food intake [66,67]. Furthermore, IL-1β can directly stimulate lipolysis, contributing thereby to weight loss and changes in body composition [68].
Our study has some limitations. It was conducted in a small group of patients. In addition, the majority of participants were directed towards biological treatment, which impacts inflammatory parameters. Therefore, serum cytokine measurements in these patients should be interpreted with caution.
In light of our study, the assessed biomarkers may be useful in controlling the activity of IBD and the nutritional status of patients, which is crucial for the success of therapy. Our results suggest a relationship between elevated IL-6 levels and the nutritional status of IBD patients, especially those with abnormal body fat. We did not show a correlation between IL-6 levels and BMI, which indicates a need to assess body composition in these patients. BMI does not verify body fat content, which is crucial in assessing the nutritional status and relevant to ongoing inflammatory processes. Furthermore, we showed an association between IL-6 and IL-1β levels and non-intentional weight reduction in patients. Thus, the determination of IL-6 and IL-1β levels in patients with IBD may provide extra information regarding the anthropometric assessment of their nutritional status.
Furthermore, we found a relationship between IL-10 levels and disease activity in IBD patients. Higher mean levels were observed in patients in remission and with a mild course. In contrast, we did not confirm a relationship between IL-10 levels and nutritional status in IBD patients, regardless of the applied method. From our observations, we can claim that inflammation reduces IL-10 levels.

5. Conclusions

IL-6 and IL-1β levels appeared to be predictors of changes in body composition, and IL-6 alone is also a predictor of body fat content in IBD patients, regardless of the commonly used markers of nutritional status, such as BMI or waist circumference. They may provide extra information regarding the nutritional status of these patients. In light of our study, IL-10 can be considered a non-invasive biomarker of IBD activity.

Author Contributions

Conceptualization, E.M.-W. and M.G.; methodology, E.M.-W. and M.G.; software, E.G.; M.G. and K.W.; validation, M.G. formal analysis, E.M.-W. and M.G.; investigation, M.G.; resources, M.G. and E.G.; data curation, M.G. and K.W.; writing—original draft preparation, M.G.; writing—review and editing, M.G. and E.M.-W.; supervision, M.G., E.G. and E.M.-W. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by grant No. 503/1-002-01/503-11-001-19-00 from the Medical University of Lodz, Poland.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zagórowicz, E.; Walkiewicz, D.; Kucha, P.; Perwieniec, J.; Maluchnik, M.; Wieszczy, P.; Reguła, J. Nationwide data on epidemiology of inflammatory bowel disease in Poland between 2009 and 2020. Pol. Arch. Intern. Med. 2022, 132, 16194. [Google Scholar] [CrossRef] [PubMed]
  2. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017, 390, 2769–2778. [Google Scholar] [CrossRef] [PubMed]
  3. Agrawal, M.; Jess, T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United Eur. Gastroenterol. J. 2022, 10, 1113–1120. [Google Scholar] [CrossRef] [PubMed]
  4. Dinarello, C.A.; Novick, D.; Kim, S.; Kaplanski, G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 2013, 8, 289. [Google Scholar] [CrossRef] [PubMed]
  5. Sims, J.E.; Smith, D.E. The IL-1 family: Regulators of immunity. Nat. Rev. Immunol. 2010, 10, 89–102. [Google Scholar] [CrossRef]
  6. Pizarro, T.T.; Michie, M.H.; Bentz, M.; Woraratanadharm, J.; Smith, M.F., Jr.; Foley, E.; Moskaluk, C.A.; Bickston, S.J.; Cominelli, F. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: Expression and localization in intestinal mucosal cells. J. Immunol. 1999, 162, 6829–6835. [Google Scholar] [CrossRef]
  7. Jarmakiewicz-Czaja, S.; Zielińska, M.; Sokal, A.; Filip, R. Genetic and epigenetic etiology of inflammatory bowel disease: An update. Genes 2022, 13, 2388. [Google Scholar] [CrossRef]
  8. Kanai, T.; Watanabe, M.; Okazawa, A.; Nakamaru, K.; Okamoto, M.; Naganuma, M.; Ishii, H.; Ikeda, M.; Kurimoto, M.; Hibi, T. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn’s disease. Gastroenterology 2000, 119, 1514–1523. [Google Scholar] [CrossRef]
  9. Andersen, N.N.; Jess, T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J. Gastroenterol. 2013, 19, 7561–7568. [Google Scholar] [CrossRef]
  10. Papoutsopoulou, S.; Campbell, B.J. Epigenetic modifications of the nuclear factor kappa B signalling pathway and its impact on inflammatory bowel disease. Curr. Pharm. Des. 2021, 27, 3702–3713. [Google Scholar] [CrossRef]
  11. Kuenzig, M.E.; Fung, S.G.; Marderfeld, L.; Mak, J.W.Y.; Kaplan, G.G.; Ng, S.C.; Wilson, D.C.; Cameron, F.; Henderson, P.; Kotze, P.G.; et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: Systematic review. Gastroenterology 2022, 162, 1147–1159.e4. [Google Scholar] [CrossRef] [PubMed]
  12. Benchimol, E.I.; Mack, D.R.; Nguyen, G.C.; Snapper, S.B.; Li, W.; Mojaverian, N.; Quach, P.; Muise, A.M. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014, 147, 803–813.e7. [Google Scholar] [CrossRef]
  13. Panufnik, P.; Więcek, M.; Kaniewska, M.; Lewandowski, K.; Szwarc, P.; Rydzewska, G. Selected aspects of nutrition in the prevention and treatment of iInflammatory bowel disease. Nutrients 2022, 14, 4965. [Google Scholar] [CrossRef] [PubMed]
  14. Elhag, D.A.; Kumar, M.; Saadaoui, M.; Akobeng, A.K.; Al-Mudahka, F.; Elawad, M.; Al Khodor, S. Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response. Int. J. Mol. Sci. 2022, 23, 6966. [Google Scholar] [CrossRef] [PubMed]
  15. Grossberg, L.B.; Papamichael, K.; Cheifetz, A.S. Review article: Emerging drug therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2022, 55, 789–804. [Google Scholar] [CrossRef]
  16. Lamano, J.B.; Lamano, J.B.; Li, Y.D.; DiDomenico, J.D.; Choy, W.; Veliceasa, D.; Oyon, D.E.; Fakurnejad, S.; Ampie, L.; Kesavabhotla, K.; et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin. Cancer Res. 2019, 25, 3643–3657. [Google Scholar] [CrossRef]
  17. Xu, Y.H.; Zhu, W.M.; Guo, Z. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World. J. Gastroenterol. 2022, 28, 6888–6899. [Google Scholar] [CrossRef]
  18. McElvaney, O.J.; Curley, G.F.; Rose-John, S.; McElvaney, N.G. Interleukin-6: Obstacles to targeting a complex cytokine in critical illness. Lancet Respir. Med. 2021, 9, 643–654. [Google Scholar] [CrossRef]
  19. Neurath, M.F. Current and emerging therapeutic targets for IBD. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 269–278. [Google Scholar] [CrossRef]
  20. Aschenbrenner, D.; Quaranta, M.; Banerjee, S.; Ilott, N.; Jansen, J.; Steere, B.; Chen, Y.H.; Ho, S.; Cox, K.; Arancibia-Cárcamo, C.V.; et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut 2021, 70, 1023–1036. [Google Scholar] [CrossRef]
  21. Shouval, D.S.; Biswas, A.; Kang, Y.H.; Griffith, A.E.; Konnikova, L.; Mascanfroni, I.D.; Redhu, N.S.; Frei, S.M.; Field, M.; Doty, A.L.; et al. Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients with Interleukin 10 Receptor Deficiency. Gastroenterology 2016, 151, 1100–1104. [Google Scholar] [CrossRef] [PubMed]
  22. Cantor, M.J.; Nickerson, P.; Bernstein, C.N. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am. J. Gastroenterol. 2005, 100, 1134–1142. [Google Scholar] [CrossRef] [PubMed]
  23. Mihara, M.; Hashizume, M.; Yoshida, H.; Suzuki, M.; Shiina, M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. 2012, 122, 143–159. [Google Scholar] [CrossRef] [PubMed]
  24. Yao, X.; Huang, J.; Zhong, H.; Shen, N.; Faggioni, R.; Fung, M.; Yao, Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 2014, 141, 125–139. [Google Scholar] [CrossRef] [PubMed]
  25. White, J.R.; Phillips, F.; Monaghan, T.; Fateen, W.; Samuel, S.; Ghosh, S.; Moran, G.W. Review article: Novel oral-targeted therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2018, 47, 1610–1622. [Google Scholar] [CrossRef] [PubMed]
  26. Veenbergen, S.; Li, P.; Raatgeep, H.C.; Lindenbergh-Kortleve, D.J.; Simons-Oosterhuis, Y.; Farrel, A.; Costes, L.M.M.; Joosse, M.E.; van Berkel, L.A.; de Ruiter, L.F.; et al. IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4+ T cells: Relevance to inflammatory bowel disease. Mucosal Immunol. 2019, 12, 1201–1211. [Google Scholar] [CrossRef]
  27. Lin, Z.; Wang, Z.; Hegarty, J.P.; Lin, T.R.; Wang, Y.; Deiling, S.; Wu, R.; Thomas, N.J.; Floros, J. Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease. World. J. Gastroenterol. 2017, 23, 4897–4909. [Google Scholar] [CrossRef]
  28. Saraiva, M.; Vieira, P.; O’Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 2020, 217, e20190418. [Google Scholar] [CrossRef]
  29. Rasquinha, M.T.; Sur, M.; Lasrado, N.; Reddy, J. IL-10 as a Th2 Cytokine: Differences Between Mice and Humans. J. Immunol. 2021, 207, 2205–2215. [Google Scholar] [CrossRef]
  30. Steen, E.H.; Wang, X.; Balaji, S.; Butte, M.J.; Bollyky, P.L.; Keswani, S.G. The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Adv. Wound. Care 2020, 9, 184–198. [Google Scholar] [CrossRef]
  31. Glocker, E.O.; Kotlarz, D.; Klein, C.; Shah, N.; Grimbacher, B. IL-10 and IL-10 receptor defects in humans. Ann. NY Acad. Sci. 2011, 1246, 102–107. [Google Scholar] [CrossRef] [PubMed]
  32. Strisciuglio, C.; Giugliano, F.P.; Martinelli, M.; Cenni, S.; Greco, L.; Staiano, A.; Miele, E. Impact of environmental and familial factors in a cohort of pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2016, 64, 569–574. [Google Scholar] [CrossRef]
  33. Gajendran, M.; Loganathan, P.; Catinella, A.P.; Hashash, J.G. A comprehensive review and update on Crohn’s disease. Dis. Mon. 2018, 64, 20–57. [Google Scholar] [CrossRef] [PubMed]
  34. Glinkowski, S.; Marcinkowska, D. Ulcerative colitis: Assessment of disease activity based on contemporary scales. Nowa Med. 2018, 25, 123–137. [Google Scholar] [CrossRef]
  35. Polińska, B.; Matowicka-Karna, J.; Kemona, H. The cytokines in inflammatory bowel disease. Postępy Hig. Med. Doświadczalnej 2009, 63, 389–394. [Google Scholar]
  36. Sobolewska-Włodarczyk, A.; Włodarczyk, M.; Talar, M.; Wiśniewska-Jarosińska, M.; Gąsiorowska, A.; Fichna, J. The association of the quality of sleep with proinflammatory cytokine profile in inflammatory bowel disease patients. Pharmacol. Rep. 2021, 73, 1660–1669. [Google Scholar] [CrossRef]
  37. Wędrychowicz, A.; Tomasik, P.; Zając, A.; Fyderek, K. Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis. Arch. Med. Sci. 2018, 14, 107–114. [Google Scholar] [CrossRef]
  38. Matusiewicz, M.; Neubauer, K.; Bednarz-Misa, I.; Gorska, S.; Krzystek-Korpacka, M. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis. World J. Gastroenterol. 2017, 23, 4039–4046. [Google Scholar] [CrossRef]
  39. Kallen, K.J. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 2002, 1592, 323–343. [Google Scholar] [CrossRef]
  40. Schumertl, T.; Lokau, J.; Rose-John, S.; Garbers, C. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochim. Biophys. Acta Mol. Cell Res. 2022, 1869, 119143. [Google Scholar] [CrossRef]
  41. Dong, Y.; Xu, T.; Xiao, G.; Hu, Z.; Chen, J. Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease. Front. Bioeng. Biotechnol. 2022, 10, 909591. [Google Scholar] [CrossRef] [PubMed]
  42. Katsanos, K.H.; Papamichael, K.; Feuerstein, J.D.; Christodoulou, D.K.; Cheifetz, A.S. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin. Immunol. 2019, 206, 9–14. [Google Scholar] [CrossRef]
  43. García-Juárez, M.; Camacho-Morales, A. Defining the role of anti- and pro-inflammatory outcomes of interleukin-6 in mental health. Neuroscience 2022, 492, 32–46. [Google Scholar] [CrossRef]
  44. Lubecka-Macura, A.; Kohut, M. TNF superfamily-mechanisms of action, biologic funtions and therapeutic possibilities. Gastroenterol. Rev. 2010, 5, 303–309. [Google Scholar] [CrossRef]
  45. Wędrychowicz, A.; Fyderek, K.; Stopyrowa, J. Stool and serum interleukin 1b and interleukin receptor antagonist and laboratory disease markers in children with active ulcerative colitis. Pediatr. Wsp. Gastroenterol. Hepatol. 2002, 4, 369–372. [Google Scholar]
  46. Gurram, B.; Salzman, N.H.; Kaldunski, M.L.; Jia, S.; Li, B.U.; Stephens, M.; Sood, M.R.; Hessner, M.J. Plasma-induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment-naive paediatric inflammatory bowel disease. Clin. Exp. Immunol. 2016, 184, 36–49. [Google Scholar] [CrossRef] [PubMed]
  47. Rodríguez-Perálvarez, M.L.; García-Sánchez, V.; Villar-Pastor, C.M.; González, R.; Iglesias-Flores, E.; Muntane, J.; Gómez-Camacho, F. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm. Bowel Dis. 2012, 18, 1864–1871. [Google Scholar] [CrossRef]
  48. Toptygina, A.P.; Semikina, E.L.; Bobyleva, G.V.; Miroshkina, L.V.; Petrichuk, S.V. Cytokine profile in children with inflammatory bowel disease. Biochemistry 2014, 79, 1371–1375. [Google Scholar] [CrossRef]
  49. Łodyga, M.; Maciejewska, K.; Stawczyk-Eder, K.; Eder, P.; Dobrowolska, A.; Wiśniewska-Jarosińska, M.; Gąsiorowska, A.; Cicha, M.; Rydzewska, G. Assessment of the activity of the immune system in patients with inflammatory bowel diseases and asymptomatic COVID-19. Gastroenterol. Rev. 2023. [Google Scholar] [CrossRef]
  50. Woźniak-Stolarska, B.; Sajewicz, Z.; Błachut, K. Poziom interleukiny 10 (IL10) w surowicy krwi w zapalnych chorobach jelit. Gastroenterol. Pol. 2002, 9, 94. [Google Scholar]
  51. Melgar, S.; Yeung, M.; Bas, A.; Forsberg, G.; Suhr, O.; Oberg, A.; Hammarstrom, S.; Danielsson, A.; Hammarstrom, M.L. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin. Exp. Immunol. 2003, 134, 127–137. [Google Scholar] [CrossRef] [PubMed]
  52. Meng, D.; Liang, L.; Guo, X. Serum interleukin-10 level in patients with inflammatory bowel disease: A meta-analysis. Eur. J. Inflamm. 2019, 17, 2058739219843405. [Google Scholar] [CrossRef]
  53. Liu, R.; Nikolajczyk, B.S. Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. Front. Immunol. 2019, 10, 1587. [Google Scholar] [CrossRef] [PubMed]
  54. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 2007, 117, 175–184. [Google Scholar] [CrossRef] [PubMed]
  55. Wu, H.; Ballantyne, C.M. Metabolic Inflammation and Insulin Resistance in Obesity. Circ. Res. 2020, 126, 1549–1564. [Google Scholar] [CrossRef] [PubMed]
  56. Gordon, S.; Martinez, F.O. Alternative activation of macrophages: Mechanism and functions. Immunity 2010, 32, 593–604. [Google Scholar] [CrossRef]
  57. Ziora, K.; Świder, M.; Mazur, B.; Oświęcimska, J. Stężenia IL-6, TNF-α i INF-γ we krwi u dziewcząt z zaburzeniami odżywiania (jadłowstręt psychiczny contra otyłość). Endokrynol. Pediatryczna 2013, 3, 31–46. [Google Scholar] [CrossRef]
  58. Ling, S.C.; Griffiths, A.M. Nutrition in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 2000, 3, 339–344. [Google Scholar] [CrossRef]
  59. Gassull, M.A. Nutrition and inflammatory bowel disease: Its relation to pathophysiology, outcome and therapy. Dig. Dis. 2003, 21, 220–227. [Google Scholar] [CrossRef]
  60. Allende, L.M.; Corell, A.; Manzanares, J.; Madruga, D.; Marcos, A.; Madroño, A.; López-Goyanes, A.; García-Pérez, M.A.; Moreno, J.M.; Rodrigo, M.; et al. Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. Immunology 1998, 94, 543–551. [Google Scholar] [CrossRef]
  61. Costa, R.G.F.; Caro, P.L.; de Matos-Neto, E.M.; Lima, J.D.C.C.; Radloff, K.; Alves, M.J.; Camargo, R.G.; Pessoa, A.F.M.; Simoes, E.; Gama, P.; et al. Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia Sarcopenia Muscle 2019, 10, 1116–1127. [Google Scholar] [CrossRef] [PubMed]
  62. Martin, A.; Freyssenet, D. Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: Lessons from human and animal studies. J. Cachexia Sarcopenia Muscle 2021, 12, 252–273. [Google Scholar] [CrossRef] [PubMed]
  63. Rocha, R.; Santana, G.; Almeida, N.; Lyra, A. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br. J. Nutr. 2008, 101, 676–679. [Google Scholar] [CrossRef] [PubMed]
  64. Argilés, J.M.; Busquets, S.; López-Soriano, F.J. Cytokines in the pathogenesis of cancer cachexia. Curr. Opin. Clin. Nutr. Metab. Care 2003, 6, 401–406. [Google Scholar] [CrossRef]
  65. Gutiérrez-Cuevas, J.; Sandoval-Rodriguez, A.; Meza-Rios, A.; Monroy-Ramírez, H.C.; Galicia-Moreno, M.; García-Bañuelos, J.; Santos, A.; Armendariz-Borunda, J. Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge. Cells 2021, 10, 629. [Google Scholar] [CrossRef]
  66. Gutiérrez-Cuevas, J.; Santos, A.; Armendariz-Borunda, J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int. J. Mol. Sci. 2021, 22, 11629. [Google Scholar] [CrossRef]
  67. Plata-Salaman, C.R. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000, 16, 1009–1012. [Google Scholar] [CrossRef]
  68. Grabiec, K.; Burchert, M.; Milewska, M.; Błaszczyk, M.; Grzelkowska-Kowalczyk, K. Systemic and local mechanisms leading to cachexia in cancer. Post. Hig. Med. Doświadczalnej 2013, 67, 1397–1409. [Google Scholar] [CrossRef]
Table 1. General characteristics of study participants.
Table 1. General characteristics of study participants.
IBD
N(%)/Mean ± SD		Controls
N(%)/Mean ± SD
CD 48 (58.5)-
UC34 (41.5)-
Age (years)38.1 ± 11.633.6 ± 9.1
Female42 (51.2)15 (60)
Level of education
Secondary42 (51.2)4 (16) *
High40 (48.8)21 (84) *
Current smoking 14 (17.1)3 (12)
Disease duration 8.4 ± 5.7-
Past intestinal resection 22 (26.8)-
Weight lost during last 6 months (%)50 (60.9)/16.5 ± 8.2-
Anthropometry
BMI (kg/m2)24.23 ± 4.7624.64 ± 3.97
<18.510 (12.2)3 (12)
18.5–24.938 (46.3)11 (44)
25.0–29.926 (31.7)9 (36)
>30.08 (9.8)2 (8)
Waist circumference (cm)88.9 ± 14.585.3 ± 9.1
Normal57 (69.5)18 (72)
High25 (30.5)7 (28)
Fatty tissue (%)27.1 ± 9.630.1 ± 8.6 *
Low14 (17.1)2 (8) *
Normal59 (71.9)15 (60) *
High9 (11.0)8 (32) *
Free fat mass (%)72.1 ± 11.269.9 ± 8.6 *
Water (%)55.1 ± 6.553.8 ± 4.1
Low 26 (31.7)10 (40) *
Normal 56 (68.3)15 (60) *
Muscle mass (kg)43.4 ± 13.743.6 ± 9.6
Medications
Biological therapy 66 (80.5)-
Immunosuppression 33 (40.2)-
Steroids25 (30.5)-
5-ASA 64 (78.0)-
Disease activity
Self-reported clinical stage of disease -
Remission 40 (48.8)-
Moderate27 (32.9)-
Active15 (18.3)-
UC
Partial Mayo Score (0/1/2/3) 17 (50.0)/0 (0)/11 (32.4)/6 (17.6)-
Montreal classification
E1/E2/E34 (11.8)/16 (47.0)/14 (41.2)-
S0/S1/S2/S3 -
12 (35.3)/10 (29.4)/11 (32.4)/3 (8.8)
CD
CDAI (0/1/2/3)17 (35.4)/10 (20.9)/17 (35.4)/4 (8.3)-
Montreal classification -
A1/A2/A38 (16.7)/36 (75)/4 (8.3)
L1/L2/L317 (35.4)/7 (14.6)/24 (50)/0 (0)-
B1/B2/B321 (43.8)/18 (37.5)/15 (3.2)-
* p < 0.05.
Table 2. Concentrations of IL-6, IL-1 β and IL-10 in the study participants.
Table 2. Concentrations of IL-6, IL-1 β and IL-10 in the study participants.
Analyzed MarkerStudy GroupStatistical Parameterp-Value *
MeanSDMedianQ1–Q3Min.–Max.
Il-6
(pg/mL)		CD13.4621.165.903.85–7.200.40–96.900.7484
UC19.2049.345.654.40–7.400.60–272.40
Control15.6814.168.804.70–27.604.10–42.70
Il-1 beta
(pg/mL)		CD11.6118.232.922.77–9.911.65–82.290.9038
UC12.5116.982.942.26–14.92 0.89–57.89
Control10.1611.193.172.77–21.981.91–30.40
Il-10
(pg/mL)		CD13.8919.622.311.90–20.090.73–68.950.0063 **
UC19.8324.148.052.25–24.051.47–90.10
Control5.306.603.101.80–5.100.72–25.20
* Statistical significance for the model used. All between-group comparisons were controlled for the patients’ age and gender. ** Post-hoc multiple comparisons. Il-10, CD vs. UC p = 0.4132; UC vs. controls p = 0.0096; CD vs. controls p = 0.1270.
Table 3. Concentrations of IL-6, IL-1 β and IL-10 according to basic clinical characteristics of patients with IBD.
Table 3. Concentrations of IL-6, IL-1 β and IL-10 according to basic clinical characteristics of patients with IBD.
IL-6 (pg/mL)
Me [Q1–Q3]		IL-1β (pg/mL)
Me [Q1–Q3]		IL-10 (pg/mL)
Me [Q1–Q3]
Disease duration
< 55.9 [3.9–7.4]2.9 [2.7–3.0]2.1 [1.9–11.6]
5–105.2 [4.6–7.4]2.9 [2.2–3.0]2.5 [2.1–23.9]
>105.9 [3.9–7.0]9.6 [2.8–39.4]14.7 [2.2–48.0]
p-value0.95330.0300 *
0.0011 **		0.0314 *
Biology therapy
YES5.1 [4.4–6.9]2.9 [2.6–12.2]2.5 [1.9–23.9]
NO6.6 [4.0–15.0]2.9 [2.8–18.6]2.5 [2.1–11.9]
p-value0.0067 *0.63140.8699
Surgery
YES5.7 [3.9–6.3]2.8 [2.4–3.1]2.3 [2.0–14.7]
NO5.9 [4.4–7.5]2.9 [2.7–12.7]2.7 [2.0–23.7]
p-value0.78940.37080.3002
* Univariate analyses. Post-hoc multiple comparisons. IL-1β, <5 vs. 5–10 NS; <5 vs. >10 p = 0.2185; 5–10 vs. >10 p = 0.0291. IL-10, <5 vs. 5–10 p = 0.3316; <5 vs. >10 p = 0.0280; 5–10 vs. >10 NS. ** A multivariate analysis, involving all the investigated factors, controlled for age and gender.
Table 4. Concentrations of IL-6, IL-1 β and IL-10 according to UC activity.
Table 4. Concentrations of IL-6, IL-1 β and IL-10 according to UC activity.
IL-6 (pg/mL)
Me [Q1–Q3]		IL-1β (pg/mL)
Me [Q1–Q3]		IL-10 (pg/mL)
Me [Q1–Q3]
Partial Mayo Score
05.3 [4.4–7.4]2.9 [2.6–37.4]23.6 [2.3–48.6]
26.0 [5.4–6.9]3.0 [2.1–26.2]3.4 [2.3–14.7]
34.4 [3.7–7.7]2.8 [2.3–3.0]2.2 [1.9–2.6]
p-value0.28600.3700.0059 *
Montreal Classification
E15.6 [5.1–59.9]7.9 [2.3–27.4]35.0 [19.4–56.8]
E25.9 [4.6–6.9]2.9 [2.1–12.2]2.6 [2.2–23.6]
E35.9 [3.7–7.7]3.0 [2.8–26.2]2.6 [2.1–17.4]
p-value0.83370.85630.1118
S06.0 [4.6–53.9]2.9 [2.3–41.7]24.0 [2.6–46.4]
S14.8 [4.4–5.3]3.0 [2.8–12.2]14.7 [2.1–19.8]
S25.9 [4.5–6.9]3.0 [2.2–26.2]2.4 [2.2–11.6]
S37.7 [7.7–7.7]2.6 [2.3–2.9]2.0 [1.5–2.6]
p-value0.11300.80130.0022 *
* Univariate analyses. Post-hoc multiple comparisons. Il-10, Mayo Score 0 vs. 2 p = 0.0373; 0 vs. 3 p = 0.0099322233243; 2 vs. 3 p =0.6219. Il-10, S0 vs. S1 p = 0.1769; S0 vs. S2 p = 0.0083; S0 vs. S3 p = 0.0675; S1 vs. S2 p = 0.0090; S1 vs. S3 p = 0.0292; S2 vs. S3 p = 0.7779.
Table 5. Concentrations of IL-6, IL-1 β and IL-10 according to Montreal classification of CD activity.
Table 5. Concentrations of IL-6, IL-1 β and IL-10 according to Montreal classification of CD activity.
IL-6 (pg/mL)
Me [Q1–Q3]		IL-1β (pg/mL)
Me [Q1–Q3]		IL-10 (pg/mL)
Me [Q1–Q3]
Age at onset (years)
A1 < 166.1 [4.9–6.6]3.0 [2.8–3.5]17.1 [2.2–34.1]
A2 17–405.9 [3.8–7.4]2.9 [2.7–3.1]2.2 [1.8–13.6]
A3 > 404.0 [3.0–50.8]2.9 [2.8–25.5]2.1 [1.8–33.2]
p-value0.66310.53730.3924
Localization
L1 Ileum5.0 [3.8–6.5]2.9 [2.9–9.6]2.2 [1.9–13.6]
L2 Colon 6.6 [4.9–7.6]2.4 [2.0–2.9]11.4 [1.8–37.0]
L3 Ileum + colon5.9 [3.8–6.6]2.9 [2.8–10.9]2.3 [1.8–19.5]
p-value0.52910.22070.7955
Course of the disease
B1 No stenoses or fistulas5.9 [3.9–7.4]2.9 [2.7–10.2]8.6 [1.9–37.0]
B2 Stenoses5.7 [4.4–6.3]2.9 [2.8–3.0]2.2 [1.8–2.3]
B3 Fistulas6.1 [5.5–7.6]2.9 [2.7–3.0]2.2 [1.8–8.0]
Perianal lesions6.1 [2.6–9.0]2.7 [2.4–14.1]11.2 [2.1–28.5]
p-value0.60290.93370.1095
CDAI
<1505.9 [3.9–18.8]3.0 [2.9–19.1]8.5 [1.9–32.0]
150–2206.3 [4.7–7.4]2.9 [2.3–3.0]1.8 [1.7–2.9]
221–4504.9 [3.3–6.1]2.9 [2.7–2.9]2.3 [2.0–19.5]
>4505.9 [5.9–35.2]2.8 [2.6–2.9]2.3 [1.9–2.6]
p-value0.30000.28100.0462 *
* A univariate analysis. Post-hoc multiple comparisons. Il-10, CDAI < 150 vs. CDAI 150–220, p = 0.0373; CDAI < 150 vs. CDAI 221–450, p = 0.0129; CDAI < 150 vs. CDAI > 450, p = 0.0034; CDAI 150–220 vs. CDAI 221–450, p = 0.9732; CDAI 150–220 vs. CDAI > 450, p = 0.2332; CDAI 221–450 vs. CDAI > 450, p =0.5239.
Table 6. Concentrations of IL-6, IL-1 β and IL-10 according to nutritional status of patients with IBD.
Table 6. Concentrations of IL-6, IL-1 β and IL-10 according to nutritional status of patients with IBD.
IL-6 (pg/mL)
Me [Q1–Q3]		IL-1β (pg/mL)
Me [Q1–Q3]		IL-10 (pg/mL)
Me [Q1–Q3]
BMI [kg/m2]
<18.56.1 [5.9–22.3]2.9 [2.8–3.0]6.2 [2.3–20.1]
18.5–24.95.2 [4.4–6.3]2.9 [2.3–10.9]2.3 [1.9–19.3]
>255.3 [3.7–7.7]2.9 [2.8–13.2]2.3 [2.1–23.9]
>308.7 [5.6–34.3]6.6 [2.6–25.7]22.3 [5.1–44.6]
p-value0.13460.58810.4926
Waist circumference [cm]
Normal5.9 [4.4–6.6]2.9 [2.5–10.9]2.3 [1.9–19.8]
High5.5 [3.9–18.8]3.0 [2.8–14.9]14.9 [2.1–46.0]
p-value0.47270.26270.1499
Weight reduction in 6 months [%]
<104.9 [3.8–6.7]2.9 [2.3–3.1]2.3 [1.9–20.8]
>105.9 [4.9–22.3]3.0 [2.8–37.4]3.5 [2.2–23.9]
p-value0.0479 *
0.1445 **		0.0486 *
0.0052 **		0.3108
Adipose tissue [%]
Low5.7 [4.4–7.7]3.0 [2.8–26.2]8.0 [2.3–20.6]
Normal4.6 [3.4–5.9]2.8 [2.3–3.0]2.4 [1.9–19.8]
High6.2 [5.9–23.92.9 [2.8–13.2]2.3 [2.0–42.7]
p-value0.0084 *
0.0466 **		0.26620.3960
Water content [%]
Low5.4 [4.4–7.4]2.9 [2.5–12.2]2.3 [1.9–23.6]
Normal5.9 [3.8–22.3]2.9 [2.7–26.2]4.4 [2.2–20.6]
p-value0.73700.67960.3371
* Univariate analyses. Post-hoc multiple comparisons. Il-6, low vs. normal p = 0.0102; low vs. high p = 0.0078; normal vs. high p = 0.0415. ** Multivariate analyses involved all the above-mentioned factors, stratifying by CD vs. UC and controlling for age and gender.
Table 7. Spearman’s correlations coefficients for the investigated cytokines in the study cohort.
Table 7. Spearman’s correlations coefficients for the investigated cytokines in the study cohort.
IL-6 (pg/mL)IL-1β (pg/mL)
All participants
IL-6 (pg/mL)--
IL-1β (pg/mL)0.3238 **-
IL-10 (pg/mL)0.2616 *0.3308 **
CD
IL-6 (pg/mL)--
IL-1β (pg/mL)0.3155 *-
IL-10 (pg/mL)0.4129 **0.3914 **
UC
IL-6 (pg/mL)--
IL-1β (pg/mL)0.3372-
IL-10 (pg/mL)0.03230.2762
* p < 0.001. ** p < 0.0001.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Godala, M.; Gaszyńska, E.; Walczak, K.; Małecka-Wojciesko, E. Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease. J. Clin. Med. 2023, 12, 5956. https://doi.org/10.3390/jcm12185956

AMA Style

Godala M, Gaszyńska E, Walczak K, Małecka-Wojciesko E. Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine. 2023; 12(18):5956. https://doi.org/10.3390/jcm12185956

Chicago/Turabian Style

Godala, Małgorzata, Ewelina Gaszyńska, Konrad Walczak, and Ewa Małecka-Wojciesko. 2023. "Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease" Journal of Clinical Medicine 12, no. 18: 5956. https://doi.org/10.3390/jcm12185956

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop